ARXX Therapeutics ApS — Credit Rating and Financial Key Figures

ARXX Therapeutics ApS (CVR number: 40868151) is a company from HERLEV. The company reported a net sales of 3.7 mDKK in 2025, demonstrating a growth of 43.5 % compared to the previous year. The operating profit percentage was at 24.4 % (EBIT: 0.9 mDKK), while net earnings were 706.6 kDKK. The profitability of the company measured by Return on Assets (ROA) was 55.7 %, which can be considered excellent and Return on Equity (ROE) was 52.9 %, which can be considered excellent. The equity ratio, a key indicator for solidity, stood at 87.6 %, a level that can be considered to be very good, which means that the majority of assets are financed by equity. ARXX Therapeutics ApS's liquidity measured by quick ratio was 26 which is at a very high level. Thus, the company demonstrates exceptional financial stability, possessing a significant surplus of liquid assets over its short-term liabilities.